Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Delivered Record Annual Revenue with Full-Year Net PEDMARK® Product Sales of $44.6 Million, Representing 50% Year-Over-Year Growth, and Q4 2025 ...

Companies Like Fennec Pharmaceuticals (NASDAQ:FENC) Can Afford To Invest In Growth

So should Fennec Pharmaceuticals (NASDAQ:FENC) shareholders be worried about its cash burn? For the purpose of this article, we'll define cash burn as the amount of cash the compa ...

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q4 2025 earnings call transcript

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q4 2025 Earnings Call Transcript March 24, 2026 Fennec Pharmaceuticals Inc. misses on earnings expectations. Reported EPS is $-0.11 EPS, expectations were $0.

Fennec Pharmaceuticals earnings are imminent; these most accurate analysts revise forecasts ahead of earnings call

Fennec Pharmaceuticals Inc. FENC will release earnings results for its fourth quarter, before the opening bell on Tuesday, ...
American Association of Individual Investors

Why Fennec Pharmaceuticals Inc.’s (FENC) Stock Is Down 11.95%

As of Tuesday, March 24, Fennec Pharmaceuticals Inc.’s FENC share price has dipped by 11.95%, which has investors questioning ...
Drug Store News

Fennec Pharmaceuticals reaches settlement with Cipla resolving Pedmark patent litigation

Cipla will not enter the market with its generic sodium thiosulfate product until Sept.1, 2033, or earlier under certain ...

Fennec Pharmaceuticals Signals Costly Push Toward Growth

Detailed price information for Fennec Pharmaceuticals Inc (FENC-Q) from The Globe and Mail including charting and trades.

Fennec Pharmaceuticals Inc (FENC) Q4 2025 Earnings Call Highlights: Record Sales and Strategic ...

Fennec Pharmaceuticals Inc (FENC) reports a 75% increase in Q4 net product sales, debt-free status, and strategic market expansions amid rising expenses.